857904-02-0

Basic information

• Product Name: L-Valine, N-(methoxycarbonyl)-3-methyl-, 2-[[4-(2-pyridinyl)phenyl]methyl]hydrazide
• CAS NO: 857904-02-0
• Molecular Formula: C20H26N4O3
• Molecular Weight: 370.451
• Mol File: 857904-02-0.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: L-Valine, N-(methoxycarbonyl)-3-methyl-, 2-[[4-(2-pyridinyl)phenyl]methyl]hydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: L-Valine, N-(methoxycarbonyl)-3-methyl-, 2-[[4-(2-pyridinyl)phenyl]methyl]hydrazide(857904-02-0)
• EPA Substance Registry System: L-Valine, N-(methoxycarbonyl)-3-methyl-, 2-[[4-(2-pyridinyl)phenyl]methyl]hydrazide(857904-02-0)

Safety Data

• Hazardous Substances Data: 857904-02-0(Hazardous Substances Data)

Upstream product

• 1003888-24-1 (S)-[2,2-dimethyl-1-(4-pyridin-2-yl-benzylidene-hydrazinocarbonyl)-propyl]-carbamic acid methyl ester 
• 127406-56-8 4-(2'-pyridyl)benzaldehyde 
• 198904-78-8 methyl (S)-(1-hydrazinyl-3,3-dimethyl-1-oxobutan-2-yl)carbamate 
• 24856-58-4 1,1-dimethoxy-1-(4-bromophenyl)methane 
• 857904-00-8 (S)-(1-hydrazinocarbonyl-2,2-dimethyl-propyl)-carbamic acid methyl ester hydrochloride 
• 198904-77-7 (S)-N'-(2-methoxycarbonylamino-3,3-dimethyl-butyryl)-hydrazinecarboxylic acid tert-butyl ester 
• 162537-11-3 (S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoic acid 
• 20859-02-3 L-tert-Leucine 
• 857904-01-9 Methyl (1S)-2,2-dimethyl-1-({(2E)-2-[4-(2-pyridinyl)benzylidene]hydrazino}carbonyl)propylcarbamate 
• 198904-85-7 N-1-(tert-butoxycarbonyl)-N-2-[4-(pyridine-2-yl)benzyl]hydrazine 
• 920757-34-2 1-(4-(pyridin-2-yl)benzyl)hydrazine 

Downstream Products

• 1313358-26-7 methyl (1R,3S)-3-((2S,3S)-3-hydroxy-4-(2-((S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl)-1-(4-(pyridin-2-yl)benzyl)hydrazinyl)-1-phenylbutan-2-ylcarbamoyl)-2,2-dimethylcyclobutylcarbamate 
• 1313358-27-8 methyl (S)-1-(2-((2S,3S)-3-((1S,3R)-3-(tert-butoxycarbonylamino)-2,2-dimethylcyclobutanecarboxamido)-2-hydroxy-4-phenylbutyl)-2-(4-(pyridin-2-yl)benzyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 
• 1313358-28-9 methyl (S)-1-(2-((2S,3S)-3-((1S,3R)-3-acetamido-2,2-dimethylcyclobutanecarboxamido)-2-hydroxy-4-phenylbutyl)-2-(4-(pyridin-2-yl)benzyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 
• 1313358-29-0 methyl (S)-1-(2-((2S,3S)-2-hydroxy-3-((1R,3S)-3-(methoxycarbonylamino)-2,2-dimethylcyclobutanecarboxamido)-4-phenylbutyl)-2-(4-(pyridin-2-yl)benzyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 
• 1313358-30-3 methyl (S)-1-(2-((2S,3S)-3-((1R,3S)-3-(tert-butoxycarbonylamino)-2,2-dimethylcyclobutanecarboxamido)-2-hydroxy-4-phenylbutyl)-2-(4-(pyridin-2-yl)benzyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 
• 1313358-31-4 methyl (S)-1-(2-((2S,3S)-3-((1R,3S)-3-(benzyloxycarbonylamino)-2,2-dimethylcyclobutanecarboxamido)-2-hydroxy-4-phenylbutyl)-2-(4-(pyridin-2-yl)benzyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 
• 1292296-09-3 1-[4-(pyridin-2-yl)phenyl]-2,5-bis{[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane 
• 198904-31-3 atazanavir 
• 1365541-63-4 methyl ((S)-1-(2-(2-((3R,4R)-3-benzyl-4-hydroxy-1-((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-2-oxopyrrolidin-3-yl)ethyl)-2-(4-(pyridin-2-yl)benzyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate 
• 1365541-62-3 methyl ((S)-1-(2-(2-((3R,4S)-3-benzyl-4-hydroxy-1-((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-2-oxopyrrolidin-3-yl)ethyl)-2-(4-(pyridin-2-yl)benzyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate 
• 857904-03-1 {(1S,2S)-1-benzyl-2-hydroxy-3-[N'-((S)-2-methoxycarbonylamino-3,3-dimethyl-butyryl)-N-(4-pyridin-2-yl-benzyl)-hydrazino]-propyl}-carbamic acid tert-butyl ester 

Relevant articles and documents

Method for synthesis of atazanavir

The invention discloses a method for synthesis of atazanavir. The method comprises that a compound methyl (S)-1-((S)-2-ethoxyethyl-1-phenylethane-2-yl-amino)-3, 3-dimethyl-1-carbonylbutane-2-yl-carbamate shown in the formula V and a compound N-1-[N-(methoxycarbonyl)-L-tertiary leucine]-N-2-[4-(2-pyridyl)-benzyl]hydrazine shown in the formula VIII undergo a nucleophilic substitution reaction in anorganic solvent to produce a compound 1-[4-(2-pyridyl)phenyl]-5(S)-2, 5-bis{[N-(methoxycarbonyl)-L-tertiary leucine]amino}-4(S)-hydroxy-6-phenyl-2-azahexane VIII shown in the formula IX, wherein the compound shown in the formula IX is atazanavir. The method utilizes raw materials having a wide raw material source, the product is easy to purify, a cost is low, the synthesis processes are simple, the operation is simple, the process is simple, special requirement on equipment is avoided and large-scale production feasibility is realized.

Synthesis of P1′-functionalized macrocyclic transition-state mimicking HIV-1 protease inhibitors encompassing a tertiary alcohol

Seven novel tertiary alcohol containing linear HIV-1 protease inhibitors (PIs), decorated at the para position of the benzyl group in the P1′ side with (hetero)aromatic moieties, were synthesized and biologically evaluated. To study the inhibition and antiviral activity effect of P1-P3 macrocyclization, 14-and 15-membered macrocyclic PIs were prepared by ring-closing metathesis of the corresponding linear PIs. The macrocycles were more active than the linear precursors and compound 10f, with a 2-thiazolyl group in the P1′ position, was the most potent PI of this new series (Ki 2.2 nM, EC 50 0.2 μM). Co-crystallized complexes of both linear and macrocyclic PIs with the HIV-1 protease enzyme were prepared and analyzed.

Process for Synthesizing Atazanavir

This invention relates to a process for synthesizing Atazanvir, including novel intermediates and novel steps to various intermediates along the synthetic pathway.